SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced ...

SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced ...

Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) ...

Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci ...

ABS-301 targeting an undisclosed immuno-oncology target discovered through ABSAI's reverse immunology platform showed expression across squamous cell carcinomas. Our first in vivo target ...

Dogs that have oral squamous cell carcinomas often need surgery that disfigures their jaws and lower their quality of ...

Lung cancer rates vary by subtype and adenocarcinoma incidence worldwide, likely due to differences in air pollution, smoking, and generational patterns.

A collaborative research team from The University of Hong Kong (HKU) and West China Hospital of Sichuan University has made a breakthrough in understanding the spread of oral squamous cell carcinoma ...

The greater the number of risk factors in patients with cutaneous squamous cell carcinoma, the higher the likelihood of poor ...

With its combination of nostalgia and heartwarming comedy, Happy Days brought viewers back to the 1950s for 11 seasons ...

The investigational therapy has been administered to over 740 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the ...

AbTree Biologics AG has signed an exclusive co-development and commercialization partnership with Shilpa Biologicals Pvt Ltd.